Centrally Acting Therapies for Irritable Bowel Syndrome

Gastroenterology Clinics of North America

Volumn 40, Issue 1, 2011, Pages 183-206

  Grover, Madhusudan ^a   Drossman, Douglas A ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antidepressants; Behavioral treatments; Irritable bowel syndrome; Psychotropic agents; Treatment

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FAMOTIDINE; FLUOXETINE; IMIPRAMINE; MILNACIPRAN; MOSAPRIDE CITRATE; NORTRIPTYLINE; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; AGITATION; ANALGESIC ACTIVITY; ANTICHOLINERGIC SYNDROME; ARTICLE; CLINICAL PROTOCOL; COGNITIVE THERAPY; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; FATIGUE; FIBROMYALGIA; HOSTILITY; HUMAN; HYPNOSIS; HYPOTENSION; INSOMNIA; IRRITABLE COLON; LIVER DYSFUNCTION; LOW DRUG DOSE; MINDFULNESS MEDITATION; NAUSEA; NIGHT SWEAT; NIGHTMARE; NONHUMAN; PSYCHODYNAMIC INTERPERSONAL THERAPY; PSYCHOLOGICAL ASPECT; PSYCHOTHERAPY; RELAXATION TRAINING; RISK FACTOR; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE ATTEMPT; TACHYCARDIA; TREATMENT INDICATION; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 79951562467     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2010.12.003     Document Type: Review

References (108)

1. Drossman D.A., Camilleri M., Mayer E.A., et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002, 123(6):2108-2131.
2. Mayer E.A., Naliboff B.D., Craig A.D. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006, 131(6):1925-1942.
3. Spiller R. Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: alterations in 5-HT signalling and metabolism in human disease. Neurogastroenterol Motil 2007, 19(Suppl 2):25-31.
4. Mayer E.A., Tillisch K., Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006, 24(6):919-933.
5. Clouse R.E., Lustman P.J. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut 2005, 54(9):1332-1341.
6. Whitehead W.E., Levy R.L., von K.M., et al. The usual medical care for irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20(11/12):1305-1315.
7. Canavan J.B., Bennett K., Feely J., et al. Significant psychological morbidity occurs in irritable bowel syndrome: a case-control study using a pharmacy reimbursement database. Aliment Pharmacol Ther 2009, 29(4):440-449.
8. Faresjo A., Grodzinsky E., Johansson S., et al. Self-reported use of pharmaceuticals among patients with irritable bowel syndrome in primary care. J Manag Care Pharm 2008, 14(9):870-877.
9. Drossman D.A., Morris C.B., Schneck S., et al. International survey of patients with IBS: symptom features and their severity, health status, treatments, and risk taking to achieve clinical benefit. J Clin Gastroenterol 2009, 43(6):541-550.
10. Camilleri M., Mangel A.W., Fehnel S.E., et al. Primary endpoints for irritable bowel syndrome trials: a review of performance of endpoints. Clin Gastroenterol Hepatol 2007, 5(5):534-540.
11. Drossman D.A. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom Med 1998, 60(3):258-267.
12. Drossman D.A. The "organification" of functional GI disorders: implications for research. Gastroenterology 2003, 124(1):6-7.
13. Grover M., Herfarth H., Drossman D.A. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin Gastroenterol Hepatol 2009, 7(1):48-53.
14. Lydiard R.B. Irritable bowel syndrome, anxiety, and depression: what are the links?. J Clin Psychiatry 2001, 62(Suppl 8):38-45.
15. Drossman D.A. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006, 130(5):1377-1390.
16. Drossman D.A., Li Z., Leserman J., et al. Health status by gastrointestinal diagnosis and abuse history. Gastroenterology 1996, 110(4):999-1007.
17. Drossman D.A., Talley N.J., Olden K.W., et al. Sexual and physical abuse and gastrointestinal illness: review and recommendations. Ann Intern Med 1995, 123(10):782-794.
18. Drossman D.A., Whitehead W.E., Toner B.B., et al. What determines severity among patients with painful functional bowel disorders?. Am J Gastroenterol 2000, 95(4):974-980.
19. Posserud I., Agerforz P., Ekman R., et al. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress. Gut 2004, 53(8):1102-1108.
20. Drossman D.A. Mind over matter in the postinfective irritable bowel. Gut 1999, 44(3):306-307.
21. North C.S., Downs D., Clouse R.E., et al. The presentation of irritable bowel syndrome in the context of somatization disorder. Clin Gastroenterol Hepatol 2004, 2(9):787-795.
22. Drossman D.A. Brain imaging and its implications for studying centrally targeted treatments in IBS: a primer for gastroenterologists. Gut 2005, 54(5):569-573.
23. North C.S., Hong B.A., Alpers D.H. Relationship of functional gastrointestinal disorders and psychiatric disorders: implications for treatment. World J Gastroenterol 2007, 13(14):2020-2027.
24. Ford A.C., Talley N.J., Schoenfeld P.S., et al. Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009, 58(3):367-378.
25. Jailwala J., Imperiale T.F., Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000, 133(2):136-147.
26. Lesbros-Pantoflickova D., Michetti P., Fried M., et al. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2004, 20(11-12):1253-1269.
27. Clouse R.E., Lustman P.J., Geisman R.A., et al. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther 1994, 8(4):409-416.
28. Kuiken S.D., Tytgat G.N., Boeckxstaens G.E. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003, 1(3):219-228.
29. Siproudhis L., Dinasquet M., Sebille V., et al. Differential effects of two types of antidepressants, amitriptyline and fluoxetine, on anorectal motility and visceral perception. Aliment Pharmacol Ther 2004, 20(6):689-695.
30. Drossman D.A., Toner B.B., Whitehead W.E., et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003, 125(1):19-31.
31. Creed F., Fernandes L., Guthrie E., et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003, 124(2):303-317.
32. Tabas G., Beaves M., Wang J., et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004, 99(5):914-920.
33. Valet M., Gundel H., Sprenger T., et al. Patients with pain disorder show gray-matter loss in pain-processing structures: a voxel-based morphometric study. Psychosom Med 2009, 71(1):49-56.
34. Blankstein U., Chen J., Diamant N.E., et al. Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 2010, 138(5):1783-1789.
35. Brunoni A.R., Lopes M., Fregni F. A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression. Int J Neuropsychopharmacol 2008, 11(8):1169-1180.
36. Geddes J.R., Carney S.M., Davies C., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361(9358):653-661.
37. Drossman D.A. Beyond tricyclics: new ideas for treating patients with painful and refractory functional gastrointestinal symptoms. Am J Gastroenterol 2009, 104(12):2897-2902.
38. Halpert A., Dalton C.B., Diamant N.E., et al. Clinical response to tricyclic antidepressants in functional bowel disorders is not related to dosage. Am J Gastroenterol 2005, 100(3):664-671.
39. Otaka M., Jin M., Odashima M., et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005, 21(Suppl 2):42-46.
40. Morgan V., Pickens D., Gautam S., et al. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut 2005, 54(5):601-607.
41. Vahedi H., Merat S., Momtahen S., et al. Clinical trial: the effect of amitriptyline in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008, 27(8):678-684.
42. Bahar R.J., Collins B.S., Steinmetz B., et al. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr 2008, 152(5):685-689.
43. Abdul-Baki H., El Hajj I.I., Elzahabi L., et al. A randomized controlled trial of imipramine in patients with irritable bowel syndrome. World J Gastroenterol 2009, 15(29):3636-3642.
44. Bomholt S.F., Mikkelsen J.D., Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 2005, 48(2):252-263.
45. Su X., Gebhart G.F. Effects of tricyclic antidepressants on mechanosensitive pelvic nerve afferent fibers innervating the rat colon. Pain 1998, 76(1-2):105-114.
46. Willert R.P., Woolf C.J., Hobson A.R., et al. The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology 2004, 126(3):683-692.
47. Gorelick A.B., Koshy S.S., Hooper F.G., et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998, 275(3 Pt 1):G460-G466.
48. Choung R.S., Cremonini F., Thapa P., et al. The effect of short-term, low-dose tricyclic and tetracyclic antidepressant treatment on satiation, postnutrient load gastrointestinal symptoms and gastric emptying: a double-blind, randomized, placebo-controlled trial. Neurogastroenterol Motil 2008, 20(3):220-227.
49. Thoua N.M., Murray C.D., Winchester W.J., et al. Amitriptyline modifies the visceral hypersensitivity response to acute stress in the irritable bowel syndrome. Aliment Pharmacol Ther 2009, 29(5):552-560.
50. Drossman D.A., Ringel Y., Vogt B.A., et al. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003, 124(3):754-761.
51. Ringel Y., Drossman D.A., Leserman J.L., et al. Effect of abuse history on pain reports and brain responses to aversive visceral stimulation: an FMRI study. Gastroenterology 2008, 134(2):396-404.
52. Gorard D.A., Libby G.W., Farthing M.J. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994, 8(2):159-166.
53. Vahedi H., Merat S., Rashidioon A., et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther 2005, 22(5):381-385.
54. Tack J., Broekaert D., Fischler B., et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006, 55(8):1095-1103.
55. Talley N.J., Kellow J.E., Boyce P., et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci 2008, 53(1):108-115.
56. Masand P.S., Pae C.U., Krulewicz S., et al. A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. Psychosomatics 2009, 50(1):78-86.
57. Ladabaum U., Sharabidze A., Levin T.R., et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010, 8(1):42-48.
58. Creed F. How do SSRIs help patients with irritable bowel syndrome?. Gut 2006, 55(8):1065-1067.
59. Brennan B.P., Fogarty K.V., Roberts J.L., et al. Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study. Hum Psychopharmacol 2009, 24(5):423-428.
60. Bradley R.H., Barkin R.L., Jerome J., et al. Efficacy of venlafaxine for the long term treatment of chronic pain with associated major depressive disorder. Am J Ther 2003, 10(5):318-323.
61. Chial H.J., Camilleri M., Burton D., et al. Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003, 284(1):G130-G137.
62. van Kerkhoven L.A., Laheij R.J., Aparicio N., et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008, 6(7):746-752. [quiz: 718].
63. Chial H.J., Camilleri M., Ferber I., et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003, 1(3):211-218.
64. Fishbain D.A., Cutler R.B., Lewis J., et al. Do the second-generation "atypical neuroleptics" have analgesic properties? A structured evidence-based review. Pain Med 2004, 5(4):359-365.
65. Hamner M.B., Deitsch S.E., Brodrick P.S., et al. Quetiapine treatment in patients with posttraumatic stress disorder: an open trial of adjunctive therapy. J Clin Psychopharmacol 2003, 23(1):15-20.
66. Grover M., Dorn S.D., Weinland S.R., et al. Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders. Dig Dis Sci 2009, 54(6):1284-1291.
67. Passik S.D., Lundberg J., Kirsh K.L., et al. A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 2002, 23(6):526-532.
68. Greene B., Blanchard E.B. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol 1994, 62(3):576-582.
69. Payne A., Blanchard E.B. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol 1995, 63(5):779-786.
70. Vollmer A., Blanchard E.B. Controlled comparison of individual versus group cognitive therapy for irritable bowel syndrome. Behav Ther 1998, 29:19-23. [abstract].
71. Tkachuk G.A., Graff L.A., Martin G.L. Randomized controlled trial of cognitive-behavioral group therapy for irritable bowel syndrome in a medical setting. J Clin Psychol Med Settings 2003, 10:57-69. [abstract].
72. Kennedy T.M., Chalder T., McCrone P., et al. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technol Assess 2006, 10(19):1-67. ii-iv, ix-x.
73. Blanchard E.B., Lackner J.M., Sanders K., et al. A controlled evaluation of group cognitive therapy in the treatment of irritable bowel syndrome. Behav Res Ther 2007, 45(4):633-648.
74. Sanders K.A., Blanchard E.B., Sykes M.A. Preliminary study of a self-administered treatment for irritable bowel syndrome: comparison to a wait list control group. Appl Psychophysiol Biofeedback 2007, 32(2):111-119.
75. Lackner J.M., Jaccard J., Krasner S.S., et al. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility. Clin Gastroenterol Hepatol 2008, 6(8):899-906.
76. Hunt M.G., Moshier S., Milonova M. Brief cognitive-behavioral Internet therapy for irritable bowel syndrome. Behav Res Ther 2009, 47(9):797-802.
77. Moss-Morris R., McAlpine L., Didsbury L.P., et al. A randomized controlled trial of a cognitive behavioural therapy-based self-management intervention for irritable bowel syndrome in primary care. Psychol Med 2010, 40(1):85-94.
78. Lackner J.M., Gudleski G.D., Keefer L., et al. Rapid response to cognitive behavior therapy predicts treatment outcome in patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2010, 8(5):426-432.
79. Reme S.E., Kennedy T., Jones R., et al. Predictors of treatment outcome after cognitive behavior therapy and antispasmodic treatment for patients with irritable bowel syndrome in primary care. J Psychosom Res 2010, 68(4):385-388.
80. Lackner J.M., Jaccard J., Krasner S.S., et al. How does cognitive behavior therapy for irritable bowel syndrome work? A mediational analysis of a randomized clinical trial. Gastroenterology 2007, 133(2):433-444.
81. Lackner J.M., Lou C.M., Mertz H.R., et al. Cognitive therapy for irritable bowel syndrome is associated with reduced limbic activity, GI symptoms, and anxiety. Behav Res Ther 2006, 44(5):621-638.
82. Blanchard E.B., Greene B., Scharff L., et al. Relaxation training as a treatment for irritable bowel syndrome. Biofeedback Self Regul 1993, 18(3):125-132.
83. Keefer L., Blanchard E.B. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: results of a controlled treatment study. Behav Res Ther 2001, 39(7):801-811.
84. Boyce P.M., Talley N.J., Balaam B., et al. A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome. Am J Gastroenterol 2003, 98(10):2209-2218.
85. van der Veek P.P., van Rood Y.R., Masclee A.A. Clinical trial: short- and long-term benefit of relaxation training for irritable bowel syndrome. Aliment Pharmacol Ther 2007, 26(6):943-952.
86. Lahmann C., Rohricht F., Sauer N., et al. Functional relaxation as complementary therapy in irritable bowel syndrome: a randomized, controlled clinical trial. J Altern Complement Med 2010, 16(1):47-52.
87. Howlett S., Guthrie E. Use of farewell letters in the context of brief psychodynamic-interpersonal therapy with irritable bowel syndrome patients. Br J Psychother 2001, 18(1):52-67. [abstract].
88. Guthrie E., Creed F., Dawson D., et al. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991, 100(2):450-457.
89. Hamilton J., Guthrie E., Creed F., et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000, 119(3):661-669.
90. Hyphantis T., Guthrie E., Tomenson B., et al. Psychodynamic interpersonal therapy and improvement in interpersonal difficulties in people with severe irritable bowel syndrome. Pain 2009, 145(1-2):196-203.
91. Whorwell P.J., Prior A., Faragher E.B. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. Lancet 1984, 2(8414):1232-1234.
92. Whitehead W.E. Hypnosis for irritable bowel syndrome: the empirical evidence of therapeutic effects. Int J Clin Exp Hypn 2006, 54(1):7-20.
93. Gonsalkorale W.M., Miller V., Afzal A., et al. Long term benefits of hypnotherapy for irritable bowel syndrome. Gut 2003, 52(11):1623-1629.
94. Calvert E.L., Houghton L.A., Cooper P., et al. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002, 123(6):1778-1785.
95. Gonsalkorale W.M., Houghton L.A., Whorwell P.J. Hypnotherapy in irritable bowel syndrome: a large-scale audit of a clinical service with examination of factors influencing responsiveness. Am J Gastroenterol 2002, 97(4):954-961.
96. Lea R., Houghton L.A., Calvert E.L., et al. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2003, 17(5):635-642.
97. Palsson O.S., Turner M.J., Johnson D.A., et al. Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms. Dig Dis Sci 2002, 47(11):2605-2614.
98. Gonsalkorale W.M., Toner B.B., Whorwell P.J. Cognitive change in patients undergoing hypnotherapy for irritable bowel syndrome. J Psychosom Res 2004, 56(3):271-278.
99. Ljotsson B., Andreewitch S., Hedman E., et al. Exposure and mindfulness based therapy for irritable bowel syndrome-an open pilot study. J Behav Ther Exp Psychiatry 2010, 41(3):185-190.
100. Gaylord S.A., Whitehead W.E., Coble R.S., et al. Mindfulness for irritable bowel syndrome: protocol development for a controlled clinical trial. BMC Complement Altern Med 2009, 9:24.
101. Blanchard E.B., Schwarz S.P., Suls J.M., et al. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther 1992, 30(2):175-189.
102. Heitkemper M.M., Jarrett M.E., Levy R.L., et al. Self-management for women with irritable bowel syndrome. Clin Gastroenterol Hepatol 2004, 2(7):585-596.
103. Schwarz S.P., Blanchard E.B., Neff D.F. Behavioral treatment of irritable bowel syndrome: a 1-year follow-up study. Biofeedback Self Regul 1986, 11(3):189-198.
104. Owens D.M., Nelson D.K., Talley N.J. The irritable bowel syndrome: long-term prognosis and the physician-patient interaction. Ann Intern Med 1995, 122(2):107-112.
105. Wald A. Psychotropic agents in irritable bowel syndrome. J Clin Gastroenterol 2002, 35(Suppl 1):S53-S57.
106. Prakash C., Clouse R.E. Long-term outcome from tricyclic antidepressant treatment of functional chest pain. Dig Dis Sci 1999, 44(12):2373-2379.
107. Sayuk G.S., Elwing J.E., Lustman P.J., et al. Predictors of premature antidepressant discontinuation in functional gastrointestinal disorders. Psychosom Med 2007, 69(2):173-181.
108. Chang L., Drossman D.A. Optimizing patient care: the psychosocial interview in the irritable bowel syndrome. Clin Perspect Gastroenterol 2002, 5(6):336-341.